NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

dstock07734,

Approval of L changes everything!; ). Patients will demand use of this treatment for all types of solid tumor cancers. Why? The answer is simple. Patients will understand that L and Direct are tissue agnostic before big pharma and possibly some regulators openly admit or grant that designation. What is the $ value of that designation?; ). What is the impact on the cancer health care system and research with that designation?; ). Who would be foolish not to make their moves before that designation is “officially” granted?; ).
This is going to be so much fun for those who make it to that point as investors in this company. By the way, would Edens need to be in place if a regulator was only offering tissue agnostic classification approval based on it?; ). Manufacturing, manufacturing, manufacturing. Edens doesn’t stop approvals to produce for limited indications but think about the possibilities ; ). Best wishes.